FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma

Cancer Imaging

Volumn 15, Issue 1, 2015, Pages

  Horn, Kevin P ^a,b   Yap, Jeffrey T ^a,b   Agarwal, Neeraj ^b   Morton, Kathryn A ^a,b   Kadrmas, Dan J ^a,b   Beardmore, Britney ^a   Butterfield, Regan I ^c   Boucher, Kenneth ^b   Hoffman, John M ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

^{18< sup> F fluorodeoxyglucose (FDG); 18< sup> F fluorothymidine (FLT); Positron emission tomography (PET); Renal cell carcinoma; Response assessment; Sunitinib; Tumor metabolism; Tumor proliferation}

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; SUNITINIB; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLUORINE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG UPTAKE; FEMALE; HUMAN; KIDNEY METASTASIS; MALE; MIDDLE AGED; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA, RENAL CELL; CONTROLLED STUDY; IMAGE PROCESSING; KIDNEY NEOPLASMS; METABOLISM; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DIDEOXYNUCLEOSIDES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84940646258     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1186/s40644-015-0049-x     Document Type: Article

References (39)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471-8.
2. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003;9(1):327-37.
3. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597-605. doi: 10.1182/blood-2002-07-2307.
4. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003;9(15):5465-76.
5. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(1):25-35. doi: 10.1200/JCO.2005.02.2194.
6. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(1):16-24. doi: 10.1200/JCO.2005.02.2574.
7. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-24. doi: 10.1001/jama.295.21.2516.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
11. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(8):2785-808. doi: 10.1158/1078-0432.CCR-04-2626.
12. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18 F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2006;47(6):1059-66.
13. Kumar R, Chauhan A, Lakhani P, Xiu Y, Zhuang H, Alavi A. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging. 2005;7(6):431-9. doi: 10.1007/s11307-005-0026-z.
14. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30(9):1236-45. doi: 10.1007/s00259-003-1211-4.
15. Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol. 2002;57(1):56-62.
16. Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003;60(6):395-400.
17. Kang DE, White Jr RL, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171(5):1806-9.
18. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21(21):3995-4000.
19. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18 F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(3):439-45. doi: 10.1200/JCO.2008.17.2742.
20. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(18):6021-8. doi: 10.1158/1078-0432.CCR-10-3309.
21. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fossa SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol. 2011;23(5):339-43. doi: 10.1016/j.clon.2010.11.006.
22. Vercellino L, Bousquet G, Baillet G, Barre E, Mathieu O, Just PA, et al. 18 F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24(1):137-44. doi: 10.1089/cbr.2008.0527.
23. Caldarella C, Muoio B, Isgro MA, Porfiri E, Treglia G, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol oncol. 2014;48(3):219-27. doi: 10.2478/raon-2013-0067.
24. Farnebo J, Gryback P, Harmenberg U, Laurell A, Wersall P, Blomqvist LK, et al. Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer. 2014;14:408. doi: 10.1186/1471-2407-14-408.
25. Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2013;54(6):903-12. doi: 10.2967/jnumed.112.112201.
26. Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of [18 F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32(11):1269-75. doi: 10.1007/s00259-005-1813-0.
27. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11):1334-6. doi: 10.1038/3337.
28. Sanghera B, Wong WL, Sonoda LI, Beynon G, Makris A, Woolf D, et al. FLT PET-CT in evaluation of treatment response. Indian journal of nuclear medicine: IJNM: the official journal of the Society of Nuclear Medicine, India. 2014;29(2):65-73. doi: 10.4103/0972-3919.130274.
29. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31(12):788-9. doi: 10.1097/01.rlu.0000247310.05362.83.
30. Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, et al. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(24):7634-44. doi: 10.1158/1078-0432.CCR-11-1677.
31. Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis. 1994;170(6):1394-403.
32. Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging. 2008;10(5):271-80. doi: 10.1007/s11307-008-0151-6.
33. Reischl G, Blocher A, Wei R, Ehrlichmann W, Kuntzsch M, Solbach C, et al. Simplified, automated synthesis of 3′[18 F]fluoro-3′-deoxy-thymidine ([18 F]FLT) and simple method for metabolite analysis in plasma. Radiochim Acta. 2006;94(8):447-51. doi: 10.1524/ract.2006.94.8.447.
34. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773-82.
35. Koller M, Stahel WA. Sharpening Wald-type inference in robust regression for small samples. Computational Statistics & Data Analysis. 2011;55(8):2504-15. doi:http://dx.doi.org/10.1016/j.csda.2011.02.014.
36. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289-300. doi:citeulike-article-id:1042553 doi: 10.2307/2346101.
37. Team RDC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria; 2011.
38. Tomasi G, Rosso L. PET imaging: implications for the future of therapy monitoring with PET/CT in oncology. Curr Opin Pharmacol. 2012;12(5):569-75. doi: 10.1016/j.coph.2012.07.016.
39. Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H, et al. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci. 2013;104(8):1052-61. doi: 10.1111/cas.12176.